KRAS and metastatic colorectal cancer: It was shown to selectively inhibit metastatic colorectal cancer with the KRAS (Kirsten rat sarcoma viral oncogene homolog) mutation, inhibiting cell proliferation by inactivating both RAS/ERK and AKT/mTOR signaling (Xie et al., 2020).